Since the introduction of techniques to reliably identify antibody to the hepatitis C virus and quantitation of hepatitis C virus, there has been an increasing interest in the behavior of chronic hepatitis C infection with liver transplantation. Ninety-seven patients with chronic active hepatitis C
Large liver cell change in hepatitis B virus–related liver cirrhosis
✍ Scribed by Haeryoung Kim; Bong-Kyeong Oh; Massimo Roncalli; Chanil Park; So-Mi Yoon; Jeong Eun Yoo; Young Nyun Park
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 869 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
✦ Synopsis
Large liver cell change (LLCC) refers to microscopic lesions often found in various chronic liver diseases; however, its nature is still controversial. Thirty-four formalin-fixed and 19 fresh frozen hepatitis B virus (HBV)-related cirrhosis samples were examined for the presence of LLCC, small liver cell change (SLCC), and hepatocellular carcinoma (HCC). The cell cycle checkpoint status (p21, p27, p16, Tp53), cell dynamics (proliferating cell nuclear antigen, Ki-67, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling, M30), DNA damage (␥-H2AX [H2A histone family, member X]), telomere lengths, chromosomal instability (micronuclei index), and senescence-associated -galactosidase (SA--Gal) activity were evaluated using an in situ approach and compared to those in normal liver (n ؍ 5) and liver with chronic cholestasis (34 cases of hepatolithiasis and three cases of primary biliary cirrhosis). In HBV-related cirrhosis, the p21, p27, and p16 cell cycle checkpoint markers were activated in normal-looking cirrhotic hepatocytes (NLCH), but diminished gradually from LLCC, SLCC, to HCC, with an increase in Tp53 expression. There was a general decrease in telomere length from NLCH, LLCC, SLCC, to HCC. Micronuclei, ␥-H2AX foci, and net cellular gain were significantly increased from normal hepatocytes, NLCH, LLCC, SLCC, to HCC. The SA--Gal activity was weaker in LLCC compared to NLCH and absent in SLCC and HCC. In contrast, cholestatic LLCC showed retained expression of cell cycle checkpoint markers and decreased net cellular gain compared to adjacent normal-looking hepatocytes. HBV-related LLCC showed significantly higher Tp53 labeling index, ␥-H2AX labeling index, and micronuclei index; shorter telomere length; decreased SA--Gal activity; and increased net cellular gain compared to cholestatic LLCC. Conclusion: The nature of LLCC is rather heterogeneous depending on the biological setting. The characteristics of HBV-related LLCC are more consistent with dysplastic rather than merely reactive hepatocytes, whereas cholestatic LLCC more likely represents reactive change with more stringent cell cycle checkpoint control. (HEPATOLOGY 2009;50:752-762.) L iver cell change (dysplasia) is characterized by individually scattered or clusters of hepatocytes with atypia, measuring Ͻ1 mm in diameter which do not form circumscribed nodules (dysplastic nodules), and have been often found in chronic liver disease. 1,2 These lesions have been classified into two types: large liver cell change (LLCC) and small liver cell change (SLCC). SLCC, a lesion first proposed by Watanabe et al. in 1983,
📜 SIMILAR VOLUMES
## We evaluated the use of blood serum N-glycan fingerprinting as a tool for the diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis induced by hepatitis B virus (HBV). A group of 450 HBV-infected patients with liver fibrosis or cirrhosis with or without HCC were studied. HCC wa
We have separated circulating HBeAg into small and large molecular forms by agarose gel electrophoresis and analyzed the relationship between the two forms and other clinical features of chronic hepatitis B, especially in regard to liver cell damage. The large HBeAg accounted for 7.3% 2 3.4% of seru
Because of its importance as an indication for liver transplantation, the epidemiology of chronic hepatitis B disease is presented. Current knowledge relative to the pathobiological mechanisms of hepatitis B virusrelated liver disease are presented, followed by a discussion of the treatment modaliti